Please login to the form below

Not currently logged in
Email:
Password:

AML

This page shows the latest AML news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs dominate FDA's record-breaking year

Orphan drugs dominate FDA's record-breaking year

s IDH1 inhibitor  Tibsovo (ivosidenib) for acute myeloid leukaemia (AML), AstraZeneca’s CD22-directed cytotoxin Lumoxiti (moxetumomab pasudotox) for hairy cell leukaemia (HCL), and TaiMed Biologics’ CD4-binding antibody Trogarzo (ibalizumab)

Latest news

More from news
Approximately 12 fully matching, plus 47 partially matching documents found.

Latest Intelligence

  • Digital disruption Digital disruption

    Initially AZ and Microsoft have focused acute myeloid leukaemia (AML), simulating experiments to predict how drug combinations might be used to overcome resistance to drugs that target cell signalling in AML,

  • Deal Watch December 2016 Deal Watch December 2016

    790. Tolero Pharma (US). Dainippon Sumitomo (Japan). Acquisition with milestones. Portfolio, including alvocidib, a CDK9 inhibitor with phase II completed in AML.

  • Deal Watch July 2016 Deal Watch July 2016

    Earlier this year Jazz completed its acquisition of Celator Pharmaceuticals, acquiring a late-stage product, Vyxeos, which targets AML, and the new agreement brings complementary products to Jazz's portfolio.

  • Deal Watch June 2016 Deal Watch June 2016

    Paying $150m upfront Novartis gains access to XmAb14045 being developed for acute myeloid leukaemia (AML) and XmAb13676 in development for B-cell malignancies. ... 2 T-cell engaging XmAb bispecific antibodies: XmAb14045 for AML and XmAb13676 for B-cell

  • Deal Watch May 2016 Deal Watch May 2016

    2, 000. Celator/ Jazz. Corporate acquisition. Acquisition for $30.25 per share brings Vyxeos [nano scale liposomal formulation of cytarabine /daunorubicin] for AML, completed P3.

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

  • Actinium appoints director of clinical operations Actinium appoints director of clinical operations

    Greg's direct experience in AML and significant knowledge of clinical trial management will have an immediate impact on our capabilities that we expect will add efficiency and scale to our

  • Celgene promotes Karen Browne to haematology director Celgene promotes Karen Browne to haematology director

    She then relocated to Switzerland in March 2010, taking up the role of associate director of MDS and acute myeloid leukaemia (AML), and less than two years later was promoted to ... director with responsibility for overall MDS/AML marketing across Europe.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics